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culate TTR, and TTR 55% was defined as “lower TTR”. CHADS22 was defined as
“higher CHADS2”. Logistic regression analyses were conducted to determine the
association between comorbidities and TTR. RESULTS: We identified 23,425 pa-
tients. The mean (SD) age was 74.89.7 years, with 84.8% 65 years. The most
common comorbidities were hypertension (41.7%), diabetes (24.1%), HF (11.7%),
and stroke (11.1%). The mean (SD) TTR was 67.314.4; 18.7% of patients had
“lower TTR”. In multivariable analyses, using age, gender, hypertension, diabetes,
stroke, and region as covariates, HF was associated with “lower TTR” [adjusted OR
(95%CI)  1.41 (1.28, 1.56); p.001]. Diabetes [1.28 (1.19, 1.38); p.001], and stroke
[1.15 (1.04, 1.27); p.001] were also associated with “lower TTR”. In the second
multivariable analyses, using gender, and region as covariates, “higher CHADS2”
was associated with “lower TTR” [adjusted OR (95%CI)  1.11 (1.04, 1.18); p.001].
CONCLUSIONS:Common comorbidities that accompanyNVAF are associatedwith
“lower TTR”. HF was associated with the greatest likelihood of a “lower TTR”, fol-
lowed by diabetes, then stroke. Anticoagulation control is more challenging for
patients with these conditions. Novel agents offering a predictable dose-response
may benefit these patients.
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OBJECTIVES: Patients with Afib have higher risk of stroke than those without Afib.
Anticoagulant therapy prevents strokes in Afib, however, Afib patients with mod-
erate to severe renal impairment have been excluded from trials. The objective of
this study was to assess the distribution of renal function by estimated glomerular
filtration rate (eGFR) in Afib patients. METHODS: A retrospective, cohort design
study was conducted using an EMR database. The study period was January 1996
thru December 2010 [eligibility period: 1/2006 - 12/2009 for adults diagnosed with
Afib (ICD9 code 427.31)]. IndexDatewas first Afib diagnosis during eligibility period.
The pre-index periodwas Jan 1996 to Index and the post-index period defined as 12
months post Index. Serum creatinine measurement at Index was required. Renal
function categorized by NKF Guidelines for Stage of CKD and eGFR calculated using
Cockcroft-Gault Equation. Demographic and clinical characteristicswere collected,
baseline and follow-up renal function determined and logistic regression con-
ducted to assess predictors of renal function decline. RESULTS: A total of 61,840
Afib patients (mean age 69.8 years; 54.2% male) identified and categorized by CKD
stage (mean age; % male) at Index: Normal – 6,572 (58.5; 73.0%); Stage 1 – 10,901
(62.8; 68.6%); Stage 2 – 20,331 (71.3; 58.6%); Stage 3 – 21,105 (74.9; 39.5%); Stage 4 –
2,579 (75.1; 31.1%); Stage 5 – 352 (71.8; 48.9%). Post-index patients were categorized
by CKD stage: Normal – 11,788; Stage 1 – 2799; Stage 2 – 17,009; Stage 3 – 18,849;
Stage 4 – 2675; Stage 5 – 401 (8,319 patients with no post-index eGFR). Male gender
and increasing age and Charlson Comorbidity Index were predictors of renal func-
tion decline (10%) as well as CHD, CKD, DM, HF, HTN and proteinuria (p0.05).
CONCLUSIONS: Nearly 40% of Afib patients in this study exhibited moderate to
severe renal impairment.
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OBJECTIVES: To assess the impact of real life statin utilization on the risk of first
non-fatal myocardial infarction (MI). METHODS: Design: Case-control methodol-
ogy using the pharmacoepidemiological information system “PGRx”. Data on co-
morbidities, risk factors andmedications were obtained frommedical records and
patient telephone interviews. Setting: General practices (n371) and cardiology
centres (n60) across France. Participants: Cases were patients with the first MI 
1 month before the date of recruitment (n2238). Controls were patients seen by a
general practitioner (GP) with no restriction as to the reasons of consultation
(n2238), matched to MI cases on gender, age, frequency of visits to a doctor, date
of recruitment and personal history of non-cardiovascular chronic disease. Expo-
sure: Statin exposure was defined as any utilisation in the two-year prior to date of
MI in cases or recruitment date in controls.Main outcomemeasures: Adjusted odds
ratios (OR) of the risk of first MI was estimated by multiple conditional logistic
regression models. Comparative effectiveness and propensity to use of individual
statinmolecules were assessed. RESULTS: The use of statins was associatedwith a
lower MI risk, with adjusted OR 0.67 [95% CI 0.56 - 0.79] for current use (within 2
months before the index date) and 0.73 [0.62 –0.86] for any use within 24 months.
Among individual statins, rosuvastatin was associated with the lowest MI risk
(adjusted OR 0.49 [0.35 - 0.68] for any use in 24 months preceding the index date)
followed by simvastatin (0.62 [0.46 - 0.84]) and others. CONCLUSIONS: This is the
first major population-based field study to investigate the effect of statins on the
risk of first non-fatal MI in a real life situation. We observed similar risk reduction
as in recent meta-analyses. While most individual statin molecules displayed pro-
tective effect, their effectiveness varied depending onpatient profile and treatment
patterns.
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OBJECTIVES:Although studies have investigated the epidemiology of patientswith
atrial fibrillation (AF), research in Japan is lacking. The aim of the current studywas
to assess the patient characteristics, medication use, and comorbidities of an AF
sample from a representative data source in Japan to make broad cross-region
comparisons.METHODS:The 2008, 2009, and 2010 JapanNational Health andWell-
ness Survey (NHWS) datasets were used in this study. The NHWS is an Internet-
based survey administered to the adult population in Japan using a random strat-
ified sampling framework to ensure demographic representativeness. Only
patients who reported a diagnosis of AF (N565) in these datasets were included in
the analyses. Demographics, health characteristics, stroke risk (using the
CHA2DS2-VASc score), and comorbidities were all assessed. RESULTS: Most pa-
tients were male (83.5%), 60 years or older (77.0%), weighed 64.50 kilograms
(SD11.04), and had been diagnosed for 10.4 years (standard deviation10.6).
Nearly a fifth (19.1%) continued to smoke. Based on the CHA2DS2-VASc score, 11.5%
patients were of low stroke risk, while 35.4% and 53.1% were of moderate and high
risk, respectively. Despite this risk for stroke, only 64.2% of patients were currently
being treated for AF. Patients with AF also reported a number of comorbidities
including 87.1% with another cardiovascular condition, 67.8% with a urological
condition, 37.3% with dyspepsia, and 32.7% with pain. A total of 8.0% of patients
reported a previous myocardial infarction. CONCLUSIONS: The AF population in
Japan is somewhat unique in its dramatic gender split and lower body weight.
Additionally, most AF patients in Japan, through a combination of their behaviors
(e.g., smoking) and health characteristics, are at moderate-to-high risk for a future
stroke. Despite this risk, not all patients are being treated according to current
guidelines. Further, these patients suffer from a number of comorbidities which
can complicate treatment decisions.
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OBJECTIVES:Heart failure (HF) accounts for an excess hospitalization burden in the
United States, and consumption of health care costs. An aging population, eco-
nomic pressures with loss of regular insurance, and increasing co-morbidity
beckon a contemporary analysis of outcomeswithin a nestedMedicaid population.
METHODS: Medical/prescription/enrollment records from the Maryland State
Medicaid Managed Care Organization/Fee-for-service populations were used to
follow 18-64 year olds with a diagnosis of HF between 7-1-05 and 6-30-10 for  6
months. Cox-proportional hazard models assessed the impact of COPD, CVD,
stroke, and renal dysfunction on hospitalization risk post-HF, adjusting for demo-
graphics, disease modifying therapies for HF (ACE inhibitors, ARB, -Blockers, al-
dosterone antagonists, other CV drugs), andwhether diagnosis coincidedwith first
hospitalization. RESULTS: Of 13,192 HF patients, 71% were 45-64 years old, 44%
men, 60% African-American, 26% with first HF diagnosis at first hospitalization.
Patientswith renal dysfunctionweremore likely (HR1.12, p0.001)while patients
with COPD (HR0.85, p0.001) or stroke (HR0.64, p0.001) less likely to be hospi-
talized for HF. There was a lower hospitalization risk among patients who received
ACE inhibitors (HR0.72, p0.001), ARB (HR0.75, p0.001), -Blockers (HR0.81,
p0.001), or other CVmedications (HR0.75, p0.001). Patients diagnosed with HF
at first hospitalization were 2.33 times more likely to be re-hospitalized (p.001)
and risk also increased with age. African-Americans were more likely, than Cau-
casians (HR1.28, p0.001), other races less likely (HR0.60, p0.004), and men
(HR1.13) more likely to be hospitalized. CONCLUSIONS: Renal dysfunction con-
current with HF increased the likelihood of hospitalization, as did age,male gender
and African-American race. Understandably, HF patients on disease-modifying
therapies, but surprisingly those also diagnosed with COPD or stroke, were less
likely to be hospitalized. These findings deserve consideration as disease manage-
ment systems are developed in an era of health care transformation.
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OBJECTIVES:Volumemeasurements of the left ventricle are essential part of echo-
cardiographic diagnosis of canine heart diseases. Three-dimensional echocardiog-
raphy (3DE) has been rarely used in veterinary medicine mainly due to economic
limitations. A new technique now allows a fast semi-automatic direct measure-
ment with 3DE, additionally to the calculation of volumes according to reported
formulas, as used previously. This new method has proven in human medicine to
reveal comparable results to those obtained from the gold standardMRI. MRI is not
indicated in dogs suffering from heart failure, because of the necessity of general
anesthesia. The aim of this study was to compare results from conventional meth-
ods of echocardiographywith 3DE.METHODS: End-diastolic and end-systolic stan-
dard measurements of the left ventricle were performed in 42 healthy dogs (bea-
gles and dachshunds), including calculation of volume according to Teichholz
measurements using M-Mode, calculations of volume using single plane and bi-
plane method of discs (Simpson’s rule) with two-dimensional echocardiography
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